# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

> **NCT04067492** · PHASE2 · TERMINATED · sponsor: **R-Pharm** · enrollment: 47 (actual)

## Conditions studied

- Gout Attack

## Interventions

- **DRUG:** RPH - 104
- **DRUG:** Voltaren®

## Key facts

- **NCT ID:** NCT04067492
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-05-12
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** In view of the continuing insufficient patient recruitment in the study due to the difficult epidemiological situation and the need for rational allocation of company resources, as well as based on the results of the interim analysis.
- **Last updated:** 2022-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04067492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04067492, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04067492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*